CANCER:

Lung Cancer

PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval FDA - 4 days	atezolizumab Sensitive: A1 - Approval FDA - 4 days
EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	amivantamab-vmjw Sensitive: A1 - Approval Businesswire - 4 days	amivantamab-vmjw Sensitive: A1 - Approval Businesswire - 4 days
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	toripalimab Sensitive: C2 – Inclusion Criteria Signal Transduct Target Ther - 4 days	toripalimab Sensitive: C2 – Inclusion Criteria Signal Transduct Target Ther - 4 days
HER-2 exon 20 YVMA insertion HER-2 exon 20 YVMA insertion	Lung Adenocarcinoma LUAD	HER-2 exon 20 YVMA insertion HER-2 exon 20 YVMA insertion	Lung Adenocarcinoma LUAD	ado-trastuzumab emtansine + mobocertinib Resistant: D – Preclinical Cancer Res - 4 days	ado-trastuzumab emtansine + mobocertinib Resistant: D – Preclinical Cancer Res - 4 days
HER-2 exon 20 YVMA insertion HER-2 exon 20 YVMA insertion	Lung Adenocarcinoma LUAD	HER-2 exon 20 YVMA insertion HER-2 exon 20 YVMA insertion	Lung Adenocarcinoma LUAD	mobocertinib Resistant: D – Preclinical Cancer Res - 4 days	mobocertinib Resistant: D – Preclinical Cancer Res - 4 days
HER-2 exon 20G776>VC insertion HER-2 exon 20G776>VC insertion	Lung Adenocarcinoma LUAD	HER-2 exon 20G776>VC insertion HER-2 exon 20G776>VC insertion	Lung Adenocarcinoma LUAD	mobocertinib Sensitive: D – Preclinical Cancer Res - 4 days	mobocertinib Sensitive: D – Preclinical Cancer Res - 4 days
EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	mobocertinib Sensitive: A1 - Approval JAMA Oncol - 5 days	mobocertinib Sensitive: A1 - Approval JAMA Oncol - 5 days
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval JCO Precis Oncol - 5 days	erlotinib Sensitive: A1 - Approval JCO Precis Oncol - 5 days
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval Int J Clin Oncol - 6 days	osimertinib Sensitive: A1 - Approval Int J Clin Oncol - 6 days
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A1 - Approval J Thorac Oncol - 1 week	nivolumab + ipilimumab Sensitive: A1 - Approval J Thorac Oncol - 1 week
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	tepotinib Sensitive: A1 - Approval PharmaTimes - 6 days	tepotinib Sensitive: A1 - Approval PharmaTimes - 6 days
ALK positive ALK positive	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	ALK positive ALK positive	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	brigatinib Sensitive: C1 - Off-label Thorac Cancer - 6 days	brigatinib Sensitive: C1 - Off-label Thorac Cancer - 6 days
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	osimertinib Sensitive: C2 – Inclusion Criteria Zhongguo Fei Ai Za Zhi - 1 week	osimertinib Sensitive: C2 – Inclusion Criteria Zhongguo Fei Ai Za Zhi - 1 week
PTPRD mutation PTPRD mutation	Non Small Cell Lung Cancer NSCLC	PTPRD mutation PTPRD mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials BMC Med - 1 week	Immunotherapy Sensitive: C3 – Early Trials BMC Med - 1 week
ERBB4 mutation ERBB4 mutation	Non Small Cell Lung Cancer NSCLC	ERBB4 mutation ERBB4 mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials Mol Med - 1 week	Immunotherapy Sensitive: C3 – Early Trials Mol Med - 1 week
CDKN2A mutation + TMB-H CDKN2A mutation + TMB-H	Non Small Cell Lung Cancer NSCLC	CDKN2A mutation + TMB-H CDKN2A mutation + TMB-H	Non Small Cell Lung Cancer NSCLC	Immunotherapy Resistant: C3 – Early Trials Sci Rep - 1 week	Immunotherapy Resistant: C3 – Early Trials Sci Rep - 1 week
CDKN2A mutation + PD-L1 overexpression CDKN2A mutation + PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	CDKN2A mutation + PD-L1 overexpression CDKN2A mutation + PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	Immunotherapy Resistant: C3 – Early Trials Sci Rep - 1 week	Immunotherapy Resistant: C3 – Early Trials Sci Rep - 1 week
PD-L1 overexpression + FGFR3 amplification PD-L1 overexpression + FGFR3 amplification	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression + FGFR3 amplification PD-L1 overexpression + FGFR3 amplification	Non Small Cell Lung Cancer NSCLC	nivolumab Resistant: C4 – Case Studies Front Oncol - 1 week	nivolumab Resistant: C4 – Case Studies Front Oncol - 1 week
PD-L1 overexpression + FGFR3 amplification PD-L1 overexpression + FGFR3 amplification	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression + FGFR3 amplification PD-L1 overexpression + FGFR3 amplification	Non Small Cell Lung Cancer NSCLC	nivolumab + anlotinib Sensitive: C4 – Case Studies Front Oncol - 1 week	nivolumab + anlotinib Sensitive: C4 – Case Studies Front Oncol - 1 week
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	anlotinib Resistant: C4 – Case Studies Zhongguo Fei Ai Za Zhi - 1 week	anlotinib Resistant: C4 – Case Studies Zhongguo Fei Ai Za Zhi - 1 week
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	pembrolizumab + anlotinib Sensitive: C4 – Case Studies Zhongguo Fei Ai Za Zhi - 1 week	pembrolizumab + anlotinib Sensitive: C4 – Case Studies Zhongguo Fei Ai Za Zhi - 1 week
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A1 - Approval ESMO Open - 2 weeks	nivolumab + ipilimumab Sensitive: A1 - Approval ESMO Open - 2 weeks
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	alectinib Sensitive: A1 - Approval JAMA Netw Open - 2 weeks	alectinib Sensitive: A1 - Approval JAMA Netw Open - 2 weeks
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	bevacizumab + atezolizumab Sensitive: A1 - Approval J Thorac Oncol - 1 week	bevacizumab + atezolizumab Sensitive: A1 - Approval J Thorac Oncol - 1 week
ALK positive ALK positive	Lung Adenocarcinoma LUAD	ALK positive ALK positive	Lung Adenocarcinoma LUAD	lorlatinib Sensitive: C1 - Off-label Medicine (Baltimore) - 2 weeks	lorlatinib Sensitive: C1 - Off-label Medicine (Baltimore) - 2 weeks
ROS1 G2032R ROS1 G2032R	Non Small Cell Lung Cancer NSCLC	ROS1 G2032R ROS1 G2032R	Non Small Cell Lung Cancer NSCLC	crizotinib Resistant: C3 – Early Trials Respirol Case Rep - 2 weeks	crizotinib Resistant: C3 – Early Trials Respirol Case Rep - 2 weeks
NUP62 rs9523A>G NUP62 rs9523A>G	Non Small Cell Lung Cancer NSCLC	NUP62 rs9523A>G NUP62 rs9523A>G	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor Resistant: C3 – Early Trials Dovepress - 2 weeks	EGFR inhibitor Resistant: C3 – Early Trials Dovepress - 2 weeks
EGFR C797S EGFR C797S	Lung Adenocarcinoma LUAD	EGFR C797S EGFR C797S	Lung Adenocarcinoma LUAD	brigatinib Sensitive: C3 – Early Trials Cancer Med - 1 week	brigatinib Sensitive: C3 – Early Trials Cancer Med - 1 week
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	brigatinib Sensitive: C3 – Early Trials Cancer Med - 1 week	brigatinib Sensitive: C3 – Early Trials Cancer Med - 1 week
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	brigatinib Sensitive: C3 – Early Trials Cancer Med - 1 week	brigatinib Sensitive: C3 – Early Trials Cancer Med - 1 week
EGFR expression + KRAS G12C EGFR expression + KRAS G12C	Non Small Cell Lung Cancer NSCLC	EGFR expression + KRAS G12C EGFR expression + KRAS G12C	Non Small Cell Lung Cancer NSCLC	Tyrosine kinase inhibitor Resistant: C3 – Early Trials ESMO Open - 2 weeks	Tyrosine kinase inhibitor Resistant: C3 – Early Trials ESMO Open - 2 weeks
DVL2 rs2074216G>A DVL2 rs2074216G>A	Lung Adenocarcinoma LUAD	DVL2 rs2074216G>A DVL2 rs2074216G>A	Lung Adenocarcinoma LUAD	EGFR inhibitor Resistant: C3 – Early Trials Dovepress - 2 weeks	EGFR inhibitor Resistant: C3 – Early Trials Dovepress - 2 weeks
ARF1 rs11541557G>T ARF1 rs11541557G>T	Lung Adenocarcinoma LUAD	ARF1 rs11541557G>T ARF1 rs11541557G>T	Lung Adenocarcinoma LUAD	EGFR inhibitor Resistant: C3 – Early Trials Dovepress - 2 weeks	EGFR inhibitor Resistant: C3 – Early Trials Dovepress - 2 weeks
UHRF1 rs2261988C>A UHRF1 rs2261988C>A	Lung Adenocarcinoma LUAD	UHRF1 rs2261988C>A UHRF1 rs2261988C>A	Lung Adenocarcinoma LUAD	EGFR inhibitor Resistant: C3 – Early Trials Dovepress - 2 weeks	EGFR inhibitor Resistant: C3 – Early Trials Dovepress - 2 weeks
GHR-ALK fusion GHR-ALK fusion	Lung Adenocarcinoma LUAD	GHR-ALK fusion GHR-ALK fusion	Lung Adenocarcinoma LUAD	crizotinib Resistant: C4 – Case Studies J Int Med Res - 2 weeks	crizotinib Resistant: C4 – Case Studies J Int Med Res - 2 weeks
ALK positive ALK positive	Lung Adenocarcinoma LUAD	ALK positive ALK positive	Lung Adenocarcinoma LUAD	alectinib + brigatinib Resistant: C4 – Case Studies Medicine (Baltimore) - 2 weeks	alectinib + brigatinib Resistant: C4 – Case Studies Medicine (Baltimore) - 2 weeks
EGFR exon 19 deletion + EGFR T790M EGFR exon 19 deletion + EGFR T790M	Small Cell Lung Cancer Small Cell Lung Cancer	EGFR exon 19 deletion + EGFR T790M EGFR exon 19 deletion + EGFR T790M	Small Cell Lung Cancer Small Cell Lung Cancer	etoposide oral Sensitive: C4 – Case Studies Medicine (Baltimore) - 2 weeks	etoposide oral Sensitive: C4 – Case Studies Medicine (Baltimore) - 2 weeks
ROS1 G2032R ROS1 G2032R	Non Small Cell Lung Cancer NSCLC	ROS1 G2032R ROS1 G2032R	Non Small Cell Lung Cancer NSCLC	entrectinib Sensitive: C4 – Case Studies Respirol Case Rep - 2 weeks	entrectinib Sensitive: C4 – Case Studies Respirol Case Rep - 2 weeks
SSTR5 expression SSTR5 expression	Non Small Cell Lung Cancer NSCLC	SSTR5 expression SSTR5 expression	Non Small Cell Lung Cancer NSCLC	paclitaxel + octreotide Sensitive: D – Preclinical Thorac Cancer - 1 week	paclitaxel + octreotide Sensitive: D – Preclinical Thorac Cancer - 1 week
SSTR2 expression SSTR2 expression	Non Small Cell Lung Cancer NSCLC	SSTR2 expression SSTR2 expression	Non Small Cell Lung Cancer NSCLC	paclitaxel + octreotide Sensitive: D – Preclinical Thorac Cancer - 1 week	paclitaxel + octreotide Sensitive: D – Preclinical Thorac Cancer - 1 week
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	lorlatinib Sensitive: A1 - Approval Future Oncol - 2 weeks	lorlatinib Sensitive: A1 - Approval Future Oncol - 2 weeks
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval Int J Cancer - 3 weeks	afatinib Sensitive: A1 - Approval Int J Cancer - 3 weeks
EGFR exon 20 insertion + EGFR T790M EGFR exon 20 insertion + EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR exon 20 insertion + EGFR T790M EGFR exon 20 insertion + EGFR T790M	Non Small Cell Lung Cancer NSCLC	afatinib Resistant: C3 – Early Trials Int J Cancer - 3 weeks	afatinib Resistant: C3 – Early Trials Int J Cancer - 3 weeks
PD-L1 overexpression + KRAS mutation PD-L1 overexpression + KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 overexpression + KRAS mutation PD-L1 overexpression + KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab + abemaciclib Sensitive: C3 – Early Trials JTO Clinical and Research Reports - 3 weeks	pembrolizumab + abemaciclib Sensitive: C3 – Early Trials JTO Clinical and Research Reports - 3 weeks
SLC8A1-ALK fusion SLC8A1-ALK fusion	Lung Adenocarcinoma LUAD	SLC8A1-ALK fusion SLC8A1-ALK fusion	Lung Adenocarcinoma LUAD	crizotinib Resistant: C4 – Case Studies Dovepress - 3 weeks	crizotinib Resistant: C4 – Case Studies Dovepress - 3 weeks
RB1 deletion RB1 deletion	Mesothelioma Mesothelioma	RB1 deletion RB1 deletion	Mesothelioma Mesothelioma	BI 6727 Sensitive: D – Preclinical Cancer Discov - 3 weeks	BI 6727 Sensitive: D – Preclinical Cancer Discov - 3 weeks
RB1 deletion RB1 deletion	Mesothelioma Mesothelioma	RB1 deletion RB1 deletion	Mesothelioma Mesothelioma	MLN8237 Sensitive: D – Preclinical Cancer Discov - 3 weeks	MLN8237 Sensitive: D – Preclinical Cancer Discov - 3 weeks
NF2 mutation NF2 mutation	Mesothelioma Mesothelioma	NF2 mutation NF2 mutation	Mesothelioma Mesothelioma	verteporfin Sensitive: D – Preclinical Cancer Discov - 3 weeks	verteporfin Sensitive: D – Preclinical Cancer Discov - 3 weeks
LATS1 mutation LATS1 mutation	Mesothelioma Mesothelioma	LATS1 mutation LATS1 mutation	Mesothelioma Mesothelioma	verteporfin Sensitive: D – Preclinical J Biol Chem - 3 weeks	verteporfin Sensitive: D – Preclinical J Biol Chem - 3 weeks
LATS2 mutation LATS2 mutation	Mesothelioma Mesothelioma	LATS2 mutation LATS2 mutation	Mesothelioma Mesothelioma	verteporfin Sensitive: D – Preclinical J Biol Chem - 3 weeks	verteporfin Sensitive: D – Preclinical J Biol Chem - 3 weeks
RASSF7 amplification RASSF7 amplification	Mesothelioma Mesothelioma	RASSF7 amplification RASSF7 amplification	Mesothelioma Mesothelioma	verteporfin Sensitive: D – Preclinical J Biol Chem - 3 weeks	verteporfin Sensitive: D – Preclinical J Biol Chem - 3 weeks
HER-2 exon 20 mutation HER-2 exon 20 mutation	Non Small Cell Lung Cancer NSCLC	HER-2 exon 20 mutation HER-2 exon 20 mutation	Non Small Cell Lung Cancer NSCLC	HM 78136B Sensitive: B - Late Trials J Clin Oncol - 3 weeks	HM 78136B Sensitive: B - Late Trials J Clin Oncol - 3 weeks
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval	afatinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval	osimertinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	ramucirumab Sensitive: A1 - Approval	ramucirumab Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval	gefitinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: A1 - Approval	durvalumab Sensitive: A1 - Approval
No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: A1 - Approval	nivolumab + ipilimumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: A1 - Approval	brigatinib Sensitive: A1 - Approval
KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	sotorasib Sensitive: A1 - Approval	sotorasib Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval	osimertinib Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: A1 - Approval	brigatinib Sensitive: A1 - Approval
ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	entrectinib Sensitive: A1 - Approval	entrectinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	bevacizumab Sensitive: A1 - Approval	bevacizumab Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval	dacomitinib Sensitive: A1 - Approval
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval	durvalumab Sensitive: A1 - Approval
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	lazertinib Sensitive: A1 - Approval	lazertinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval	dacomitinib Sensitive: A1 - Approval
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	capmatinib Sensitive: A1 - Approval	capmatinib Sensitive: A1 - Approval
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	cemiplimab Sensitive: A1 - Approval	cemiplimab Sensitive: A1 - Approval
RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	pralsetinib Sensitive: A1 - Approval	pralsetinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	cisplatin + pemetrexed Sensitive: A1 - Approval	cisplatin + pemetrexed Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval	gefitinib Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval	gefitinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	cisplatin Sensitive: A1 - Approval	cisplatin Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A1 - Approval	crizotinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A1 - Approval	crizotinib Sensitive: A1 - Approval
RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	selpercatinib Sensitive: A1 - Approval	selpercatinib Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval	afatinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: A1 - Approval	durvalumab Sensitive: A1 - Approval
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	tislelizumab Sensitive: A1 - Approval	tislelizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	DP Sensitive: A1 - Approval	DP Sensitive: A1 - Approval
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	savolitinib Sensitive: A1 - Approval	savolitinib Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval	dacomitinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval	erlotinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval	bevacizumab + atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval	Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	topotecan Sensitive: A1 - Approval	topotecan Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab Sensitive: A1 - Approval	bevacizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	pemetrexed Sensitive: A1 - Approval	pemetrexed Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval	cisplatin + pemetrexed Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	carboplatin + albumin-bound paclitaxel Sensitive: A1 - Approval	carboplatin + albumin-bound paclitaxel Sensitive: A1 - Approval
No biomarker No biomarker	Lung Adenocarcinoma LUAD	No biomarker No biomarker	Lung Adenocarcinoma LUAD	nintedanib Sensitive: A1 - Approval	nintedanib Sensitive: A1 - Approval
EGFR expression EGFR expression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	EGFR expression EGFR expression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	necitumumab Sensitive: A1 - Approval	necitumumab Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	bevacizumab + atezolizumab Sensitive: A1 - Approval	bevacizumab + atezolizumab Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Non Small Cell Lung Cancer NSCLC	BRAF V600E BRAF V600E	Non Small Cell Lung Cancer NSCLC	trametinib + dabrafenib Sensitive: A1 - Approval	trametinib + dabrafenib Sensitive: A1 - Approval
No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	pemetrexed Sensitive: A1 - Approval	pemetrexed Sensitive: A1 - Approval
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	lurbinectedin Sensitive: A1 - Approval	lurbinectedin Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	docetaxel Sensitive: A1 - Approval	docetaxel Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval	erlotinib Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ceritinib Sensitive: A1 - Approval	ceritinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval	afatinib Sensitive: A1 - Approval
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	almonertinib Sensitive: A1 - Approval	almonertinib Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + erlotinib Sensitive: A1 - Approval	bevacizumab + erlotinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	sintilimab Sensitive: A1 - Approval	sintilimab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: A1 - Approval	erlotinib + ramucirumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	erlotinib + Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval	erlotinib + Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
ALK mutation ALK mutation	Non Small Cell Lung Cancer NSCLC	ALK mutation ALK mutation	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval	erlotinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	nivolumab Sensitive: A1 - Approval	nivolumab Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: A1 - Approval	erlotinib + ramucirumab Sensitive: A1 - Approval
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	entrectinib Sensitive: A1 - Approval	entrectinib Sensitive: A1 - Approval
BRAF V600 BRAF V600	Non Small Cell Lung Cancer NSCLC	BRAF V600 BRAF V600	Non Small Cell Lung Cancer NSCLC	trametinib + dabrafenib Sensitive: A1 - Approval	trametinib + dabrafenib Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	afatinib Sensitive: A1 - Approval	afatinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	tislelizumab Sensitive: A1 - Approval	tislelizumab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	nivolumab Sensitive: A1 - Approval	nivolumab Sensitive: A1 - Approval
ALK mutation ALK mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ALK mutation ALK mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	nivolumab Sensitive: A1 - Approval	nivolumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	sintilimab Sensitive: A1 - Approval	sintilimab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A2 - Guideline	nivolumab + ipilimumab Sensitive: A2 - Guideline
EGFR mutation + ALK negative + TMB-H EGFR mutation + ALK negative + TMB-H	Non Small Cell Lung Cancer NSCLC	EGFR mutation + ALK negative + TMB-H EGFR mutation + ALK negative + TMB-H	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A2 - Guideline	nivolumab + ipilimumab Sensitive: A2 - Guideline
ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A2 - Guideline	crizotinib Sensitive: A2 - Guideline
ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	ceritinib Sensitive: A2 - Guideline	ceritinib Sensitive: A2 - Guideline
ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A2 - Guideline	crizotinib Sensitive: A2 - Guideline
No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	carboplatin + pemetrexed Sensitive: A2 - Guideline	carboplatin + pemetrexed Sensitive: A2 - Guideline
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A2 - Guideline	crizotinib Sensitive: A2 - Guideline
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	alectinib Sensitive: A2 - Guideline	alectinib Sensitive: A2 - Guideline
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	lorlatinib Sensitive: A2 - Guideline	lorlatinib Sensitive: A2 - Guideline
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A2 - Guideline	osimertinib Sensitive: A2 - Guideline
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK inhibitor Sensitive: A2 - Guideline	ALK inhibitor Sensitive: A2 - Guideline

Lung Cancer

Associations(2499)

Associations
(2499)